Related Experiment Video
Updated: Jan 13, 2026
Purification and Transplantation of Myogenic Progenitor Cell Derived Exosomes to Improve Cardiac Function in Duchenne Muscular Dystrophic Mice
Published on: April 10, 2019
Therapeutic effect of amniotic membrane mesenchymal stem cell-derived exosome-rich conditioned medium in cerebral
Eun-Jung Yoon1,2, Jiwon Jeong1, Yunseo Choi1
1Laboratory of Veterinary Toxicology, College of Veterinary Medicine, Kangwon National University, Chuncheon-si 24341, Republic of Korea.
Insights
Amniotic membrane mesenchymal stem cell-derived exosome-rich conditioned medium (ERCM) shows therapeutic potential for cerebral palsy (CP). ERCM treatment improved motor and cognitive functions and protected neural cells in CP models.
Area of Science:
- Neuroscience
- Regenerative Medicine
- Stem Cell Biology
Background:
- Cerebral palsy (CP) is a childhood neurological disorder stemming from perinatal hypoxia/ischemia, causing motor, behavioral, and cognitive impairments.
- Current treatments for CP are limited, highlighting the need for novel therapeutic strategies.
Purpose of the Study:
- To investigate the therapeutic efficacy of exosome-rich conditioned medium (ERCM) derived from amniotic membrane mesenchymal stem cells in a cerebral palsy (CP) model.
- To assess ERCM's effects on neural cell survival, inflammation, and oligodendrocyte differentiation in vitro and in vivo.
Main Methods:
- ERCM composition was analyzed; its biodistribution was tracked in normal and CP-induced animal models.
- In vitro studies assessed ERCM's neuroprotective effects on human neural stem cells and oligodendrocyte progenitor cells against induced cytotoxicity.
- In vivo studies involved injecting ERCM into CP-induced animals and evaluating functional recovery, neural integrity, and molecular markers.
Main Results:
- ERCM demonstrated a rich profile of growth factors and localized effectively in CP-affected brain regions.
- In vitro, ERCM reduced apoptosis and inflammation while promoting oligodendrocyte maturation.
- In vivo, ERCM improved motor and cognitive functions, reduced cell death and inflammation, enhanced oligodendrocyte differentiation markers, and attenuated demyelination.
Conclusions:
- ERCM exhibits significant therapeutic benefits for cerebral palsy by protecting neural stem and oligodendrocyte progenitor cells.
- ERCM modulates apoptotic and inflammatory pathways and promotes oligodendrocyte differentiation, suggesting its potential as a CP therapeutic agent.
Background:
Cerebral palsy (CP), primarily caused by perinatal cerebral hypoxia and ischemia, is a devastating neurological disease in children characterized by motor, behavioral, and cognitive disorders. This study aimed to evaluate the therapeutic effects of amniotic membrane mesenchymal stem cell-derived exosome-rich conditioned medium (ERCM) in a CP model.
Methods:
ERCM components were analyzed using enzyme-linked immunosorbent assay. Biodistribution was examined via fluorescence-labeled ERCM in both normal and CP induced animals. In vitro, the neuroprotective effects of ERCM against lipopolysaccharide and potassium cyanide-induced cytotoxicity were assessed in human neural stem cells and oligodendrocyte progenitor cells, focusing on apoptosis, inflammation, and oligodendrocyte differentiation. In vivo, ERCM was injected into CP-induced animals, followed by evaluation of antiapoptotic and anti-inflammatory signaling, motor and cognitive function, and white matter integrity.
Results:
ERCM contained a broad array of growth factors and demonstrated enhanced retention in CP-affected brain regions. In vitro, ERCM significantly reduced apoptos is and inflammation, and promoted oligodendrocyte maturation via upregulation of Nkx2.2, CN Pase, and MBP. In vivo, ERCM treatment improved motor and cognitive performance, in hibited cell death and inflammatory responses, and increased expression of oligodendrocyte markers, including Nkx2.2, Olig2, CNPase, and MBP via increasing growth factor expression. Furthermore, ERCM attenuated demyelination in the corpus callosum, a region particularly vulnerable in CP.
Conclusion:
ERCM confers therapeutic benefits in CP by preserving neural stem and oligodendrocyte progenitor cells, modulating apoptosis and inflammation, and enhancing oligodendrocyte differentiation. Accordingly, ERCM may present a good candidate as a CP therapeutic agent.
